Enrolling By InvitationNCT05427500
Stellate Ganglion Block in the Treatment of PTSD
Medication studyAges 18–69Canada
Understand this study
Who could participate?
Listed age limits: 18 years to 69 years.
- Listed locations
- OttawaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 30, 2024
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 54
- Sponsor
- The Royal's Institute of Mental Health Research
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 18 Years to 69 Years
- Official registry ID
- NCT05427500
- Official title
Show the full official title
Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: Outcome Evaluation, Mechanism of Action, and Integration in Care - A Phase III Randomized Controlled Trial
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ottawa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is The Royal's Institute of Mental Health Research, a research institute.
Does this study involve medication?
Yes. The study involves medication, including 5 mL of 0.5% preservative-free bupivacaine.
Who can participate?
Listed age limits: 18 years to 69 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
